Ruth R. Wexler Explained
Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan, a blood pressure treatment.[1]
| Ruth R. Wexler |
| Birth Place: | Pikesville, MD |
| Nationality: | American |
| Alma Mater: | University of Pennsylvania |
| Thesis Year: | 1982 |
| Doctoral Advisor: | Amos Smith |
| Known For: | cardiovascular drug development |
Education
Wexler received her B.A. in chemistry from Boston University in 1977, and a Ph.D. in organic chemistry working with Amos B. Smith at the University of Pennsylvania in 1982.[2] [3]
Research
Wexler started her career at DuPont in 1982, rising to Executive Director in 1998. She then joined Bristol-Myers Squibb as an Executive Director in 2001, moving eventually to New Jersey to head their cardiovascular research unit. She has worked on targets involved in apoptosis, inflammation, obesity, and coagulation. As of 2018, she has over 215 original research publications.[4]
Awards
- 2015 - E.B. Hershberg Award for Discoveries in Medicinally Active Substances
- 2014 - Inducted into the ACS MEDI Hall of Fame[5]
- 2011 - BMS Ondetti and Cushman Award
- 2004 - Outstanding New Jersey Woman in Research
Notes and References
- Web site: E. B. Hershberg Award For Important Discoveries In Medicinally Active Substances Chemical & Engineering News. Jarvis. Lisa. cen.acs.org. 2018-11-21.
- Web site: Ruth R. Wexler, Ph.D.. www.acsmedchem.org. 2018-11-21.
- Web site: Wexler, Ruth Amos Smith Research Group. www.sas.upenn.edu. en. 2018-11-21.
- Quan. Mimi L.. Pinto. Donald J. P.. Smallheer. Joanne M.. Ewing. William R.. Rossi. Karen A.. Luettgen. Joseph M.. Seiffert. Dietmar A.. Wexler. Ruth R.. 2018-05-18. Factor XIa Inhibitors as New Anticoagulants. Journal of Medicinal Chemistry. en. 61. 17. 7425–7447. 10.1021/acs.jmedchem.8b00173. 29775297. 0022-2623.
- Web site: MEDI Hall of Fame Inductees. www.acsmedchem.org. 2018-11-21.
